Drug Regulatory Process - Part II Flashcards

1
Q

Generic Drug Review Process:

  • Abbreviated new drug application (ANDA) is filed
  • To gain FDA approval, a generic drug must:
    1. contain the same active ingredient as the _________ drug
    2. be identical in _____, _____ form and _____ of administration
    3. have the same use _______
    4. be bioequivalent
    5. meet the same batch requirement for identity, _____, _____ & quality
    6. be manufactured under the same strict standards of FDAs good manufacturing regulations
A
  1. innovator
  2. strength, dosage, route
  3. indications
  4. strength, purity
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

OTC drug review process:

  • 6 out of 10 medication purchased
  • available without a ________ - easy access
  • > 80 classes of OTC drugs, > 100, 0000 products marketed
  • FDA - evaluates the ingredients and labels these products as part of the “ _____ _____ ______ ______ ______”
  • The _____ ________ _______ Board assists the FDA with this evaluation process
A
  • prescription
  • “The OTC Drug Review Program”
  • Nonprescription Drug Advisory Board
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Post Drug Approval:

Phase 4:

  • more information about the ____ _____ and safety of the drug when used in the general population
  • long term risks and benefits
  • efficacy when used in the general population
  • may be required by the _____
A
  1. side effects

2. FDA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Post Drug Approval:

  • a vital part of the CDER’s mission is to monitor the safety and effectiveness of drugs that are currently available
  • this is done via CDER’s :
    • division of ___________ and epidemiology
    • MEDWatch/spontaneous reporting system
    • ______________
    • contracts/ coopertaive agreements
A
  1. pharmacovigilance

2. pharmacoepidiemiology

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Post Drug Approval

  • to capture serious adverse event data, CDER recieves expeditied and periodic reports from drug manufacturers
  • MEDWatch Program - has 4 goals:
    1. make it easier for healthcare provider (HCP) to report serious events
    2. make it clearer to HCP’s what types of adverse events FDA is interested in
    3. more widely disseminate info on the FDA’s actions that have resulted from adverse event and product problem reporting
    4. increase HCP’s understanding and awareness of _____ and ______ - induced disease
A
  • drug and device
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Post Drug Approval

  • ______ ________ system contains adverse drug reaction reports from hospitals, HCP’s and lay person that are sent either directly to the Agency (via MEDwatch) or first to the _____ ________ and the by regulation to the Agency by the drug manufacturer.
A
  • spontaneous reporting

- drug manufacturer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Prescription Writing

  • divided into 2 main categories:
A
  1. inpatient (institution)

2. outpatient

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Prescription Writing

  • Inpatient Requirements:
    1. ______ _______
    2. date and _____ the script was written
    3. _______ status
    4. full name of _______ (generic name preferred)
    5. _____ must be written (mg, micrograms, units)
    6. ________ of administration (1 tab q4hrs prn)
    7. _____ of therapy (IV antibiotics)
    8. _______ for administration on all PRN medication orders (ie: prn pain)
    9. include any special parameters for medication titration, monitoring or admin (ie: clonidine 0.2mg PO TID, hold for SBP
A
  1. patient identification
  2. time
  3. allergy
  4. medication
  5. dose
  6. frequency
  7. duration
  8. reason
  9. weight, dose
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Prescription writing (things to keep in mind)

  • round to the nearest _____ increment
  • sign order with _____ name, title and _____ number
  • for verbal or telephone orders, all the receiver to ____ back the order
A
  • dosing
  • full name, pager #
  • read
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Prescription Writing: Outpatient

  1. prescription must have your name, office _____ and _____ number
  2. there should be a section for pt’s name and address and date
  3. there should be a section for ________ for the pt or the pharmacist
  4. there should be a name of the drug (generic or brand name) and _______.
  5. ____ if required
A
  1. address and telephone
  2. directions
  3. quantity
  4. refills
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Prescription Writing

  • Outpatient controlled Substances
    - same requirement as other prescriptions PLUS ______ # AND:
    * CIII-V: (allowed ____ refills or valid for ___ months -
    whichever comes first)
    * C-II: (NO _____ allowed, _____ copy required, ______
    required)
    * Laws can vary from state to state
A
  • DEA
  • CIII-V: 5 refills, 6 months
  • C-II: No refills, hard copy, signature
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Prescription Writing (this slide is informational - no answer)

  • DEA numbers
    • Class I, Class II, Class III, Class IV, Class V drugs
A

😊

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Schedules of Controlled Drugs: ?

  • high potential for abuse
  • Not currently accepted use in treatment in the in the US
  • lack of accepted safety for use of the drug or other substance under medical supervision
  • Drug examples: 2?
A
  • Class I

* heroin, marijuana

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Schedules of Controlled Drugs: ?

  • high abuse potential
  • currently ACCEPTED medical use in treatment in the US or a currently accepted medical use with severe restrictions
  • abuse may lead to severe psychological or physical _________
  • Drug examples: 3?
A
  • Class II
  • dependence
  • morphine, fentanyl, methadone
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Schedules of Controlled Drugs: ?

  • potential for abuse LESS than the classes that precede
  • currently accepted medical use in treatment in the US
  • abuse may lead to moderate or low ______ dependence or high _______ dependent
  • Drug examples: Buprenorphine, Hydrocodone/APAP (______), Codeine/APAP (________) Marinol, Testosterone products
A
  • Class III
  • (low) physical, (high) psychological
  • Lortab, Tylenol 3
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Schedules of Controlled Drugs: ?

  • low potential for abuse
  • currently accepted medical use in treatment in the US
  • abuse of the drug may lead to _______ physical or psychological dependence
  • Drug Examples: ________, Zolpidem (Ambien), __________, Propoxyphene/APAP (Darvocet-N)
A
  • Class IV
  • limited
  • Benzodiazepines, Phenobarbital
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Schedules of Controlled Drugs: ?

  • Low potential for abuse
  • currently accepted medical use in the US
  • abuse may lead to limited physical dependence or psychological dependence
  • Drug Examples: ______ ______ containing small amounts of codeine (codeine/promethazine), pregabalin (Lyrica)
A
  • Class V

* cough syrup

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Pregnancy Categories

  • based on ______ studies and/or _______ studies
  • many categories leave drugs up to the discretion of the practitioner/pt in terms of risk/benefit
  • _____ trimester risks VS. _____ trimester risks
  • Categories: A, B, C, D, X
A
  • animal, human

* 1st, 3rd

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Pregnancy Categories: ??

  • studies show NO increased risk of fetal abnormalities to the fetus in any trimester of pregnancy
  • Drug Examples: folic acid, vit B 6, levothyroxine
A
  • Category A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Pregnancy Categories: ?

  • Animal studies have revealed no evidence of harm to the fetus, however, there are NO adequate/well-controlled studies in preg women OR
  • animal studies have shown an adverse effect, but adequate/well-controlled studies in preg women show NO risk to the fetus in any trimester
  • Drug Examples: APAP, _________, insulin, Ibuprofen (before ____ trimester), amoxicillin
A
  • Category B
  • predinisone
  • 3rd
21
Q

Pregnancy Categories: ?

  • animal studies have shown an ADVERSE effect and there are NO adequate/well-controlled studies in preg women OR
  • no animal studies have been conducted and there are NO adequate and well-controlled studies in preg women
  • Drug Examples: _________, carbamazepine, ciprofloxacin, _________
A
  • Category C

* antidepressants, fluconazole

22
Q

Pregnancy Categories: ?

  • adequate/well controlled studies in pregnant women have shown RISK to the fetus
  • however, benefits of therapy may outweigh the potential risk.
    - this drug may be acceptable if needed in ____ _______ situation
    or serious disease for which safer drugs cannot be effective
    *Drug Examples: ______, _______, pheytoin, valproic acid, ACEI, tetracyline, most cancer chemo
A
  • Category D
  • life threatening
  • Alcohol
  • lithium
23
Q

Pregnancy Categories: ?

  • adequate/well-controlled studies in animals and pregnant women have demonstrated POSITIVE evidence of fetal abnormalities or risk.
  • the use of the product is ______ in women who are pregnant or may become pregnant
  • Drug Examples: Istrotretinoin (_______), thalidomide, misoprostil (cytotec)
A
  • Category X
  • contraindicated
  • accutane
24
Q

“the general study of all of the many different genes that determine drug behavior”

A
  • Pharmacogenomics
25
Q

Defects in the 1st trimester are related to?

A
  • birth defects
26
Q

Defects in the 3rd trimester are related to?

A

*disruption of the physiological change from fetus to neonate (giving ibuprofen in the 3rd trimester will close the ductus)

27
Q

” the study of inherited differences (variation) in drug metabolism and response.”

A
  • Pharmacogenetics
28
Q

“is the determination of the order of nucleotides (the base sequencse) in DNA molecule.”

A
  • DNA sequencing
29
Q

Human Genome Project - Goals

  • identified approx _____ - ______ genes in the human DNA
  • determined the sequences of the __ _____ chemical base pairs in the human DNA
  • store this information in databases
  • improve tools for data analysis
  • transfer related technologies to the _____ sector, and address the ethical, legal and social issues
A
  • 20,000 - 25,000
  • 3 billion
  • private
30
Q

Human Genome Project: Outcomes

  • human genome = ___ ______ chemical nucleotide bases (A, C. G, T)
  • 30,000 genes
  • > _____ % of all nucleotide bases is the same in all humans
A
  • 3 billion

* 99%

31
Q

SNP: Single Nucleotide Polymorphism

  • _____ _________ variations that occur when a single nucleotide (A, T, C, G) in the genome sequence is _____
    - occurs in > ___ % of the population
    - can occur in protein ______ regions
    * causes loss of protein ______
    * abnormal protein synthesis
    - can occur in ____ - ______ regions (regulatory regions)
    * abnormal rate of protein synthesis
A
  • DNA sequence, altered
  • > 1%
  • coding
  • synthesis
  • non-coding
32
Q

Pharmacokinetic Consequences of SNPs (ie: genetic variation)

  1. unexpected _______
  2. _____ of ______
  3. lack of ________
A
  1. toxicity
  2. duration of action
  3. efficacy
33
Q

Examples of Genetic Influence on Anesthetic Pharmacology:

  1. ______________ deficiency
  2. ___________ hyperthermia
  3. anesthetic requirements and different genetic backgrounds
A
  1. pseudocholinesterase

2. malignant

34
Q

Pharmacokinetic Variability:

Beta Blockers (CYP 450) ?

A
  • enhanced drug effect
35
Q

Pharmacokinetic Variability:

Codeine, dextromethorphan (CYP2D6) ?

A
  • decrease drug effect
36
Q

Pharmacokinetic Variability:

Alfentanil (CYP3A4)?

A
  • enhanced drug response
37
Q

Pharmacokinetic Variability:

Angiotensin II - Receptor Type 1 Blockers (CYP450)?

A
  • enhanced BP response
38
Q

Pharmacokinetic Variability:

Warfarin (CYP2C9)?

A
  • enhanced anticoagulant effect ( risk of bleeding)
39
Q

Pharmacokinetic Variability:

ACEI (angiotensin-1 converting enzyme)?

A
  • BP response
40
Q

Pharmacokinetic Variability:

Procainamide (NAT2)?

A
  • enhanced drug effect
41
Q

Pharmacokinetic Variability:

Succinycholine (BCHE)?

A
  • enhanced drug effect
42
Q

Pharmacokinetic Variability:

Digoxin (ABCB1, MDR1)?

A
  • increased bioavailability
43
Q

Pharmacokinetic Variability:

Beta Blockers
(B1 and B2 adrenergic receptors - ADRB1, ADRB2)?

A
  • BP and HR response

- a/w responsiveness to B2

44
Q

Pharmacokinetic Variability:

QT prolonging drugs (antiarrythimics, erythromycin, cisapride)
(Na and K ion channels)?

A
  • long QT syndrome

- risk of torsades de pointes

45
Q

Pharmacokinetic Variability:

Aspirin, glycoprotein IIb/IIa inhibitors?

A
  • variability in antiplatelet effects
46
Q

Pharmacokinetic Variability:

Phenylephrine (endothelial nitric oxide synthase) ?

A
  • BP repsonse
47
Q

Pharmacokinetic Variability:

Ca Channel Blockers (CYP450)

A
  • uncertain
48
Q

Pharmacokinetic Variability:

Phenytoin (CYP2C9)?

A
  • enhanced drug effect
49
Q

Generic Drug Review Process:

  • An important parts of the _______ mission is to assure that safe and effective generic drugs are available to American people
A
  • CDER’s